Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annu...(ctations and assumptions regarding futur...),Health

Date:5/18/2009

ctations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the Company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the company's annual report on Form 10-Q for the period ended March 31, 2009, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the Company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

TRBN-015RA

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com


    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com

'/>"/>

SOURCE Trubion Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call
2. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
3. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
4. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
5. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
8. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
10. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
11. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York